FDA Approves Novel Narcolepsy Treatment Orzeyful

The U.S. FDA has approved Orzeyful (oveporexton) for treating narcolepsy type 1 in adults. This medication is notable as the first to directly activate the brain's orexin receptor, addressing the disease's underlying biology rather than just symptoms. This approval represents a significant advancement, offering a new therapeutic approach for patients with narcolepsy type 1.